Johnson & Johnson Innovation: Decoding Disparities QuickFire ChallengeDeadline: June 25, 2021
Decoding Disparities QuickFire Challenge invites U.S.-based innovators—including entrepreneurs, health systems experts, technologists, researchers, academia, and students—to submit data-driven methodologies or technologies aiming to better detect, understand, or reduce the root causes of health inequities and inform the crucial next steps towards achieving equity.
Awardees will receive access to the JLABS network, and mentorship from experts at the Johnson & Johnson Family of Companies.
Proposed projects should be:
- Able to collect and analyze factors driving disparities that could potentially inform strategies and tactics that improve health outcomes in racial/ethnic groups and underserved populations
- Include data integration, analytics, and patient engagement to improve population health outcomes both immediately and in the long-term
- Feasible and generalizable
- Aligned to the areas of strategic focus for the Janssen Pharmaceutical Companies of Johnson & Johnson (Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension); see solicitation for details
Areas of interest include:
- Data Integration aspect of population health management—Identify gaps within communities of color that are amenable to change; Provide actionable insights to inform potential targeted interventions and resource development.
- Barriers to equitable access to health care across the patient journey including the patient/physician level and clinical encounter—Seeking care: Cultural or SDOH related barriers, symptom awareness/recognition, enablement of care-seeking behaviors; Getting diagnosed; Treatment decision-making: access to primary/specialty care, access to evidence-based interventions, barriers to initiating and maintaining treatment; Physician/Patient relationship; Appropriate support to enable patients to access, fulfill, and adhere to treatment to maximize benefits and minimize risks.
Priority focus areas for Janssen Pharmaceutical Companies of Johnson & Johnson:
- Mental Health—Black populations are disproportionately impacted by some mental health conditions and may experience detrimental medical, emotional, and physical effects due to racial profiling, among other factors.
- Inflammatory Bowel Diseases (IBD)—The incidence of IBD are increasing in non-white population, as recent trends indicate a change in the epidemiology of IBD. It is therefore important to fully understand the epidemiology and progression of IBD in different racial and ethnic groups, and the effects of race and ethnicity on access to care, utilization of resources, and disease-related outcomes.
- Cardiovascular Disease—Both Black and Native American populations have been found to be disproportionately impacted by peripheral artery disease (P.A.D.).
Amount: Awards will be made in increments of up to $200,000, $100,000, or $50,000.
Eligibility: While all potential applicants are encouraged to apply, those that are Health Care Providers, Government Officials or any organization affiliated with either, including but not limited to 501(c)3 and/or 501(c)4 entities, will be subjected to additional review and may not be ultimately eligible to participate.